|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors
Participants in this study will receive ASN004 once every 3 or 4 weeks by intravenous infusion. The ASN004 dosing schedule may be modified based on emerging data and Safety Review Committee decision. The study will test various doses of ASN004 to find out the highest safe dose to test in future trials.
Eligible subjects will be sequentially enrolled in cohorts at escalated doses.
100 Clinical Results associated with Kirilys Therapeutics, Inc.
0 Patents (Medical) associated with Kirilys Therapeutics, Inc.
100 Deals associated with Kirilys Therapeutics, Inc.
100 Translational Medicine associated with Kirilys Therapeutics, Inc.